⚖ SoapBox law
CasesDocketsStatutesRegulationsJudgesLawyersFile a complaintOversightDataLibrary

Cases

Search U.S. court opinions (CourtListener / Free Law Project), or resolve a reporter citation to its case via the Caselaw Access Project. Facts only — name, court, date, status, citation count. Never a holding-summary.

4 opinions for “GlaxoSmithKline Biologicals SA v. Pfizer Inc.”

District Court, D. New Jersey · 2007-03-20 · Published · cited 3× · 482 F. Supp. 2d 390; 2007 U.S. Dist. LEXIS 20190; 2007 WL 1146472
482 F.Supp.2d 390 (2007) PFIZER INC., Pharmacia Corp., Pharmacia & Upjohn Inc., Pharmacia & Upjohn Company, G.D. Searle & Co., G.D. Searle LLC, Searle LLC (Delaware) and Searle LLC (Nevada) Plaintiffs, v. TEVA PHARMACEUTICALS USA, INC. Defendant. No. CIV.A. 04-754(JCL). United States District Court, D. New Jersey. March 20, 2007.
District Court, N.D. California · 2014-11-17 · Published · cited 14× · 74 F. Supp. 3d 1052; 2014 U.S. Dist. LEXIS 161069; 2014 WL 6465235
ORDER GRANTING IN PART AND DENYING IN PART MOTION TO DISMISS Re: Dkt. No. 95 WILLIAM H. ORRICK, United States District Judge INTRODUCTION In this multidistrict antitrust litigation, plaintiffs challenge in their consolidated complaints a settlement between Endo Pharmaceuticals Inc. (“Endo”), a distributor of the brand-name drug Lidoderm, Tei-koku Seiyaku Co., its ma
District Court, D. Massachusetts · 2004-09-30 · Published · cited 0× · 339 F. Supp. 2d 165
MEMORANDUM AND ORDER SARIS, District Judge. I. INTRODUCTION Defendants have moved to dismiss the Amended Complaint filed by the County of Suffolk in New York in this multi-district litigation involving allegations of fraud against various pharmaceutical companies.1 Suffolk alleges that Defendant pharmaceutical manufacturers have fraudulently inflated th
Court of Appeals for the Third Circuit · 2017-08-17 · Published · cited 72× · 868 F.3d 132
OPINION OF THE COURT JORDAN, Circuit Judge. Table of Contents I.Background.... 143 A. The Hatch-Waxman Act.143 B. Factual and Procedural Background. ...145 II. Discussion... .147, A. Sham Litigation.... 147